Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
52 pending office actions • 26 art units • 49 examiners • 0 of 52 (0%) have an AI response strategy ready • 74 patents granted in the last 365 days
Bristol-Myers Squibb Company currently manages 52 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 52 actions are distributed across 49 distinct examiners, which indicates a very high degree of individual examiner variety. The involvement of 26 distinct art units further suggests that the company's intellectual property is spread across a wide range of specialized technical groups within the patent office.
The busiest examiner for this portfolio is Rahmani, Niloofar, who is currently handling 2 of the pending office actions. This small concentration of 2 actions with a single individual means that the vast majority of the portfolio is being reviewed by examiners who are only handling a single case for the entity. For practitioners, this decentralized environment requires a highly adaptable prosecution strategy, as 49 distinct examiners will likely bring a diverse array of perspectives and requirements.
With 26 distinct art units involved, the Biotechnology & Pharmaceuticals filings are subject to many different procedural standards. The 52 pending office actions reflect a broad research and development base that necessitates familiarity with numerous examination units. While Rahmani, Niloofar and her 2 pending actions represent the busiest point of contact, the overall success of the portfolio depends on navigating the 49 distinct examiners assigned to the various cases.
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (4%) |
| §101 + other | 1 (2%) |
| §103 only | 12 (23%) |
| §102 only | 1 (2%) |
| §112 only | 7 (13%) |
| Double-patenting only | 5 (10%) |
| Double-patenting + other | 8 (15%) |
| Multi-statute (no §101) | 15 (29%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 2 | 77.5% | -2.9% |
| AEDER, SEAN E | 2 | 57.0% | +19.9% |
| MAHLUM, JONATHAN DAVIS | 2 | 51.4% | +25.6% |
| GAUGER, PAUL RANDALL | 1 | 56.0% | +12.1% |
| LIU, GORDON G | 1 | 82.9% | +14.8% |
| FRONDA, CHRISTIAN L | 1 | 82.4% | +14.2% |
| KASTURE, DNYANESH G | 1 | 48.1% | +26.5% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
| KRASNOW, NICHOLAS R | 1 | 66.3% | +13.0% |
| HARANDI, SIAMAK | 1 | 90.6% | +7.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19094484 | Kaplan-Meier Digitizer for Automating Kaplan-Meier Curve Analysis | LIU, GORDON G | — |
| 19023584 | METHODS TO MANIPULATE QUALITY ATTRIBUTES OF POLYPEPTIDES PRODUCED IN CHO CELLS | FRONDA, CHRISTIAN L | — |
| 18918033 | FRAMEWORK FOR DOCUMENT LAYOUT AND INFORMATION EXTRACTION | HARANDI, SIAMAK | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17905870 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | KAUFMAN, CLAIRE M | 30d overdue |
| 18336889 | COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | KIM, YUNSOO | 19d overdue |
| 18152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | STOICA, ELLY GERALD | 3d overdue |
| 18043562 | LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA | BERHANE, SELAM | 70d |
| 18693731 | METHODS OF CONTROLLING THE LEVEL OF DISSOLVED OXYGEN (DO) IN A SOLUTION COMPRISING A RECOMBINANT PROTEIN IN A STORAGE CONTAINER | KIPOUROS, HOLLY MICHAELA | — |
| 18435117 | Compounds and Compositions for Selective Degradation of Engineered Proteins | ISMAIL, REHANA | — |
| 18294609 | CELL CULTURE METHODS FOR PRODUCING THERAPEUTIC PROTEINS | METCALF, MATTHEW CURRAN | — |
| 18531312 | USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785585 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | MAHLUM, JONATHAN DAVIS | 132d overdue |
| 18463743 | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS | AEDER, SEAN E | 44d overdue |
| 17763614 | COMPOSITE BIOMARKER FOR CANCER THERAPY | AEDER, SEAN E | 11d overdue |
| 18874740 | PERISTALTIC PUMP | KASTURE, DNYANESH G | 70d |
| 19574713 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | GAUGER, PAUL RANDALL | — |
| 19094484 | Kaplan-Meier Digitizer for Automating Kaplan-Meier Curve Analysis | LIU, GORDON G | — |
| 19023584 | METHODS TO MANIPULATE QUALITY ATTRIBUTES OF POLYPEPTIDES PRODUCED IN CHO CELLS | FRONDA, CHRISTIAN L | — |
| 18873229 | TETRAHYDROPYRIDO 3,4-D PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | COUGHLIN, MATTHEW P | — |
| Art Unit | Apps |
|---|---|
| 1625 | 5 |
| 1621 | 3 |
| 1641 | 3 |
| 1642 | 3 |
| 1647 | 2 |
| 1629 | 1 |
| 3746 | 1 |
| 1744 | 1 |
| 1691 | 1 |
| 3682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19574713 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | GAUGER, PAUL RANDALL | 1629 | DP | Non-Final OA | — | Pending | Mar 23, 2026 |
| 19094484 | Kaplan-Meier Digitizer for Automating Kaplan-Meier Curve Analysis | LIU, GORDON G | — | §103 | Non-Final OA | — | Pending | Mar 28, 2025 |
| 19023584 | METHODS TO MANIPULATE QUALITY ATTRIBUTES OF POLYPEPTIDES PRODUCED IN CHO CELLS | FRONDA, CHRISTIAN L | — | §103DP | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18874740 | PERISTALTIC PUMP | KASTURE, DNYANESH G | 3746 | §103 | Final Rejection | 70d | Pending | Dec 13, 2024 |
| 18873229 | TETRAHYDROPYRIDO 3,4-D PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | COUGHLIN, MATTHEW P | — | §112 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18857946 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | KRASNOW, NICHOLAS R | 1744 | §103 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18918033 | FRAMEWORK FOR DOCUMENT LAYOUT AND INFORMATION EXTRACTION | HARANDI, SIAMAK | — | DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18908888 | CRYSTALLINE FORMS OF A PAR4 INHIBITOR | KIFLE, BRUCK | — | DP | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18847553 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVING ORAL BIOAVAILABILITY | GULLEDGE, BRIAN M | — | §103 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18817352 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RAHMANI, NILOOFAR | — | DP | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18839079 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | JACKSON, SHAWQUIA | — | §112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18839055 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | VALENROD, YEVGENY | — | §112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18804699 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | WARD, PAUL V | — | DP | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18694424 | METHODS OF TREATING HAIR-LOSS DISORDERS WITH TYK2 INHIBITORS | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18693731 | METHODS OF CONTROLLING THE LEVEL OF DISSOLVED OXYGEN (DO) IN A SOLUTION COMPRISING A RECOMBINANT PROTEIN IN A STORAGE CONTAINER | KIPOUROS, HOLLY MICHAELA | — | §102§103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18684747 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | CHANDRAKUMAR, NIZAL S | 1625 | §103DP | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18435117 | Compounds and Compositions for Selective Degradation of Engineered Proteins | ISMAIL, REHANA | 1625 | §102§103§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18294609 | CELL CULTURE METHODS FOR PRODUCING THERAPEUTIC PROTEINS | METCALF, MATTHEW CURRAN | — | §103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18579578 | HIGH-AFFINITY SUPRAMOLECULAR POLYMERS FOR BINDING-TRIGGERED ANTIBODY PRECIPITATION AND PURIFICATION | STEPHENS, AMELIA CAROLE | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18413928 | MODIFIED SELF-IMMOLATING MOIETIES FOR USE IN PRODRUGS AND CONJUGATES AND METHODS OF USING AND MAKING | BOWLES, DAVID PAUL | — | §103§112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18389891 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | KIM, SEONG JONG | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18531312 | USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS | MOSELEY II, NELSON B | — | §102§103Other | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18526197 | Line of Therapy Identification from Clinical Documents | SOREY, ROBERT A | 3682 | §101 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18504198 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | AULAKH, CHARANJIT | 1621 | §102§103§112Other | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18041665 | METHOD OF MAKING PROTEIN | BARRON, SEAN C | 1797 | §103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18473498 | TREATMENT AND DETECTION METHODS FOR INFLAMMATORY BOWEL DISEASE | KONOPKA, CATHERINE ANNE | 1796 | §102§103§112 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18468097 | METHODS OF TREATING TUMOR | TAYLOR, LIA ELAN | 1641 | §103 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18367252 | ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 1647 | Other | Non-Final OA | 29d | Pending | Sep 12, 2023 |
| 18463743 | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS | AEDER, SEAN E | 1642 | §103Other | Non-Final OA | 44d overdue | Pending | Sep 08, 2023 |
| 18547751 | PATIENT RESPONSE-BASED BIOMARKER TOPOLOGY QUANTIFICATION AND ASSESSMENT FOR MULTIPLE TISSUE TYPES | FITZPATRICK, ATIBA O | 2677 | §101 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18271579 | COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | 12d | Pending | Jul 10, 2023 |
| 18336889 | COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | KIM, YUNSOO | 1641 | §103§112 | Final Rejection | 19d overdue | Pending | Jun 16, 2023 |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | WELLS, LAUREN QUINLAN | 1622 | §103 | Final Rejection | 26d overdue | Pending | Mar 16, 2023 |
| 18043562 | LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA | BERHANE, SELAM | 1675 | §102§112 | Non-Final OA | 70d | Pending | Feb 28, 2023 |
| 18042018 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | MOU, LIYUAN | 1628 | §102§103DP | Final Rejection | 111d overdue | Pending | Feb 17, 2023 |
| 18152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | STOICA, ELLY GERALD | 1647 | §103§112 | Non-Final OA | 3d overdue | Pending | Jan 09, 2023 |
| 17998521 | DOSING AND ADMINISTRATION OF ACTIVATABLE ANTI-CTLA-4 ANTIBODY | PETERS, ALEC JON | 1641 | §103DP | Final Rejection | 3d overdue | Pending | Nov 11, 2022 |
| 18051936 | MINIATURIZED DYSTROPHINS HAVING SPECTRIN FUSION DOMAINS AND USES THEREOF | MARVICH, MARIA | 1631 | §112 | Non-Final OA | — | Pending | Nov 02, 2022 |
| 17915593 | AUTOMATED SYSTEM AND METHOD FOR ANALYZING SAMPLES FROM A BIOREACTOR | NGUYEN, HENRY H | 1758 | §103§112 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17905870 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | KAUFMAN, CLAIRE M | 1674 | §103§112 | Non-Final OA | 30d overdue | Pending | Sep 08, 2022 |
| 17786239 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SAMSELL, RILLA MARIE | 1624 | §112 | Non-Final OA | 132d overdue | Pending | Jun 16, 2022 |
| 17785585 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | MAHLUM, JONATHAN DAVIS | 1625 | §112 | Final Rejection | 132d overdue | Pending | Jun 15, 2022 |
| 17779104 | LABEL-FREE N-GLYCAN QUANTIFICATION METHODS | FRITCHMAN, REBECCA M | 1700 | §103 | Final Rejection | — | Pending | May 23, 2022 |
| 17773425 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | MAHLUM, JONATHAN DAVIS | 1625 | §102§112 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17772865 | METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3 | LEE, YIE CHIA | 1642 | §103Other | Final Rejection | 78d | Pending | Apr 28, 2022 |
| 17763614 | COMPOSITE BIOMARKER FOR CANCER THERAPY | AEDER, SEAN E | 1642 | §103 | Final Rejection | 11d overdue | Pending | Mar 24, 2022 |
| 17760692 | DUAL CAPTURE METHOD FOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES | IVICH, FERNANDO NMN | 1678 | §112 | Non-Final OA | 71d overdue | Pending | Mar 15, 2022 |
| 17753657 | PHARMACEUTICAL FORMULATIONS OF INDOLEAMINE 2, 3-DIOXYGENASE INHIBITORS | NGUYEN, NGOC-ANH THI | 1615 | §103 | Final Rejection | — | Pending | Mar 10, 2022 |
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103§112 | Final Rejection | — | Pending | Mar 01, 2022 |
| 17613904 | METHODS OF MONITORING CELL CULTURE MEDIA | SPANGLER, JOSEPH RANKIN | 1656 | §101§103§112 | Non-Final OA | — | Pending | Nov 23, 2021 |
| 17610634 | AGONISTS OF ROR GAMMAt | BELL, SARA ELIZABETH | 1625 | §102§112 | Non-Final OA | — | Pending | Nov 11, 2021 |
| 17599433 | METHODS OF TREATING TUMOR | BUCHANAN, BAILEY CHEYENNE | 1682 | §103§112 | Non-Final OA | — | Pending | Sep 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial